➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Colorcon
McKesson
Dow

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 4,624,924

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 4,624,924
Title: Novel collagenase \"discolysin\" and production method thereof
Abstract:Disclosed herein is a novel collagenase \"discolysin\". It is useful for biochemical researches and the treatment of many diseases caused by collagen, such as hernia of intervertebral disc. It can be produced by culturing a discolysin-producing bacterium belonging to genus of Streptomyces in a culture medium and then collecting discolysin from the culture medium.
Inventor(s): Endo; Akira (Tokyo, JP)
Assignee: Kabushiki Kaisha Yakult Honsha (Tokyo, JP)
Application Number:06/708,637
Patent Claims:1. A collagenase "discolysin" having the following physical and chemical properties and produced by culturing a bacterium belonging to the genus of Streptomyces in a culture medium and then collecting discolysin from the culture medium:

(1) Molecular weight: 60,000-70,000 (SDS-Gel electrophoresis); 90,000-110,000 (SDS-Gel electrophoresis; presence of 10 mM EDTA);

(2) Formation of two collagenase-active bands by disc gel electrophoresis;

(3) Isoelectric point: pH 4.8 and 4.9 (determined by focal electrophoresis);

(4) Elemental analysis data: C, about 43%; H, about 7%; N, about 13%;

(5) U.V. spectrum: FIG. 1;

(6) I.R. spectrum: FIG. 2;

(7) Precipitated by 45-81% saturation with ammonium sulfate;

(8) Adsorbed on an ion exchanger, DEAE cellulose;

(9) Decomposes insoluble collagens and denatured collagen but is extremely inert to casein;

(10) Optimum pH for decomposition of insoluble collagens: 7.6-8.0; and

(11) Inhibited by EDTA.

2. A method for producing a novel collagenase "discolysin",as recited in claim 1, which comprises culturing a discolysin-producing bacterium belonging to the genus of Streptomyces in a culture medium and then collecting discolysin from the culture medium.

3. A method according to claim 2, wherein the discolysin-producing bacterium is Streptomyces C-51 strain.

4. The method of claim 2, wherein said culturing is conducted aerobically in a culture medium at 25.degree.-35.degree. C.

Summary for Patent: ⤷  Free Forever Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan59-45292Mar 09, 1984

Details for Patent 4,624,924

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04 ⤷  Free Forever Trial Kabushiki Kaisha Yakult Honsha (Tokyo, JP) 2004-03-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Mallinckrodt
Colorcon
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.